^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    XKDCT086

    i
    Associations
    News

    Trials

    Company:
    Celconta Group, First Condor Biotech
    Drug class:
    PD1 inhibitor, CLDN18.2-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial (NCT05952375)
    Phase N/A
    The Affiliated Hospital of Qingdao University
    Recruiting
    Last update posted :
    07/19/2023
    Initiation :
    03/01/2023
    Primary completion :
    02/28/2025
    Completion :
    02/28/2025
    CLDN18
    |
    XKDCT086